BeiGene dosed the first subject of the trial in South Korea. Credit: Diana Polekhina on Unsplash.

A collaboration between Zymeworks and BeiGene has expanded the Phase III HERIZON‑GEA‑01 clinical trial of zanidatamab for treating gastroesophageal adenocarcinomas to Asia.

BeiGene dosed the first subject of the trial in South Korea.

A bispecific antibody, zanidatamab can attach two non-overlapping HER2 epitopes at the same time, a process called biparatopic binding.

The companies signed licensing and partnership agreements in November 2018 under which BeiGene obtained an exclusive licence to research, develop and market zanidatamab and ZW49 in Asia, excluding Japan, Australia and New Zealand.

Furthermore, Zymeworks and BeiGene are partnering on joint worldwide development for specific indications to develop zanidatamab and ZW49 across various HER2-expressing malignancies and treatment options.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the first subject dosing in Asia, BeiGene will make a milestone payment of $8m to Zymeworks.

The international, randomised Phase III trial will assess the efficacy and safety of zanidatamab plus physician’s choice chemotherapy with or without tislelizumab versus trastuzumab plus physician’s choice chemotherapy as first-line therapy.

It will enrol nearly 700 patients with advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal cancers at approximately 300 study centres in 38 nations.

Progression-free survival as evaluated by blinded independent central review and overall survival will be the primary goals of the trial.

BeiGene will manage the study centres sites in Australia, New Zealand and Asia except for Japan while Zymeworks will handle sites in areas that include North and South America, Europe, Japan, Africa and the Middle East.

With an estimated enrolment period of two years, Zymeworks anticipates the filing of a supplemental Biologics Licence Application with the US Food and Drug Administration by 2024.

This October, Zymeworks and ALX Oncology dosed the first participant in the Phase Ib/II trial of Zanidatamab plus evorpacept in individuals with advanced HER2-expressing breast cancer and other solid tumours.